Merck

Why Bad News Makes the Stock Market Happy

For now, bad news is good for the stock market. Investors judged that the latest weak economic reports will make it more likely that the Fed will keep stimulating the economy

Pfizer Spins Off Zoetis, Biggest IPO Since Facebook, Shares Soar

Pfizer's animal health business Zoetis has raised about $2.2 billion in its initial public offering of 86.1 million shares, and the stock is expected to begin trading Friday. Merck & Co.'s fourth-quarter profit fell 7 percent as generic competition slashed sales of its blockbuster allergy drug Singulair.

Dow Rises Despite Europe's Woes

On Friday, it looked like this week would be ugly. Standard & Poor's had just downgraded the credit ratings of France and several other E.U. countries, the latest domino to fall in Europe's slow-motion economic train wreck. But at least in the U.S., the stock market has shrugged off that news.

A Simple Strategy to Boost Your Returns

Options: It's a word that makes you shiver with fear or salivate at opportunity. In fact, there's one options strategy that's almost certain to add some extra money to your portfolio over time, without adding lots of risk. It's the technique known as writing covered calls, and it's perfect for times like this.

Which Comes First: Jobs or Profits?

Lots of companies are laying off workers, trying to cut costs and improve their profit margins. But how should investors view the news of job cuts at a company? As a sign of deep trouble and worse to come, or as proof of committed management and better times ahead? Here's how to read the pink slips.

Top-Selling Drugs About to Lose Patent Protection

The pharmaceutical industry is about to fall off a cliff -- a patent cliff. Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from companies' bottom lines. Here's a rundown: